Nuveen’s Zomedica Corp. ZOM Stock Holding History

Nuveen’s Portfolio ZOM Stock Details ZOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,060,731	Closed	-$349K	–	3466
2021 Q4	$349K	Buy	+1,060,731	New	+$478K	﹤0.01%	3142

Other funds holding ZOM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Nuveen's ZOM Position: Q1 2022 in Review

Nuveen sold out of Zomedica Corp. (ZOM) in Q1 2022, closing a stake of 1,060,731 shares — an estimated $349K sold.

Nuveen first reported a position in ZOM in Q4 2021 and held it in 1 quarter. The position peaked at $349K in Q4 2021. 110 funds tracked by Wall St. Rank hold ZOM as of Q1 2022.

Nuveen reported no remaining Zomedica Corp. position as of Q1 2022 after selling out during the quarter.
Nuveen sold 1,060,731 Zomedica Corp. shares in Q1 2022, an estimated $349K.
Nuveen first reported a position in Zomedica Corp. in Q4 2021 and held it in 1 quarter.
Nuveen's Zomedica Corp. position peaked at $349K in Q4 2021.
110 funds tracked by Wall St. Rank held Zomedica Corp. as of Q1 2022.

Based on Nuveen's 13F filing for Q1 2022, filed 16 May 2022.